Pluristem Enters Into Licensing Agreement with TES Holdings Co., Ltd., a Venture Company Derived from the University of Tokyo
Pluristem Therapeutics Inc, a leading developer of placenta-derived cell therapy products, today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ischemic diseases with placental cell therapy rounding out the Company's IP coverage. This license follows Pluristem's recent announcement that the Japan Patent Office granted the Company two key patents addressing three-dimensional methods for...
View full press release